This site is intended for health professionals only

Boehringer Ingelheim celebrates inauguration of its new “Center of Competence”

teaser

Boehringer Ingelheim today celebrated the inauguration of its new “Center of Competence” (CoC) in Shanghai. As part of the company’s EUR 100 million expansion project in China, the CoC entails an investment of EUR 10 million and will specialise in optimising active pharmaceutical ingredients (APIs) and chemical intermediates procured in China. So far, more than 20 highly-qualified organic and analytical chemists have been recruited for the CoC.

“This reinforces our company’s determination and commitment to continue investing in China,” said Dr Wolfram Carius, Member of the Board of Managing Directors of Boehringer Ingelheim and responsible for the Board Division Human Resources and Operations. “We attach great importance to the exchange with our Chinese partners. We have a long-term commitment to this market and we are driving innovation in the country’s pharmaceutical industry.”

The new CoC consists of the two departments Process Development (PD) and Quality Control (QC). The main functions of PD are to focus on the production process optimisation and the corresponding technology transfer to the company’s partners within China in order to increase the production efficiency and precision.

David Preston, Chief Executive Officer of Boehringer Ingelheim China, said: “The inauguration of CoC is a milestone for Boehringer Ingelheim’s development in China. By optimising the production process of our partners and securing the quality of the intermediates, China will play a stronger role in the company’s global procurement efforts. With this new center of competence, Boehringer Ingelheim China now has a full-fledged business framework spanning from R&D, production, sales to international procurement.”

In 2009, the company announced a EUR 100 million expansion plan in China to expand its production capacity in Shanghai Zhangjiang High-Tech Park and to set up a new R&D facility.

Boehringer Ingelheim






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x